Shares of ResMed Inc. RMD slid 0.30% to $233.18 Friday, on what proved to be an all-around grim trading session for the stock ...

Shares of ResMed Inc. RMD inched 0.56% higher to $233.88 Thursday, on what proved to be an all-around mixed trading session ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $237.27, but opened at $230.21. ResMed shares last traded at $226 ...

Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

Chip stocks advanced, led by Broadcom ( AVGO) after UBS analysts raised their price target for the stock, citing the ...

Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its ...

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

I have to say, this list is representative of an industry that has been through a lot.

Even a medical device maker attributed their revenue growth this year in part to the rise of GLP-1 drugs. ResMed (RMD+0.34%), ...

Investment analysts at William Blair issued their Q2 2025 earnings per share estimates for shares of ResMed in a research ...

Weight-loss drugs are increasingly prescribed in the U.S., not only for obesity treatment but also to facilitate eligibility ...